

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
A051701	Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-hit and Double-expressing Lymphomas	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1826	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (ADCETRIS) plus AVD in Patients (AGE>= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A051301	A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma of the Activated B-Cell Subtype	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
ANHL12P1	COG-ANHL12P1: A Randomized Phase II study of <u>Brentuximab</u> Vedotin and <u>Crizatinib</u> in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL.) <b>Patients Must be &lt;22 Years of Age</b>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1608	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA4181	A Randomized 3 Arm Phase II Study Comparing 1.) Bendamustine + Rituximab + High Dose Cytarabine (BR/CR), 2.) Bendamustine + Rituximab + High Dose Cytarabine + Acalabrutinib (BR/CR-A) and 3.) Bendamustine + Rituximab + Acalabrutinib (BR-A) in Patients >70 years old with Untreated Mantle Cell Lymphoma	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

---

AALL1731	<b>A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
----------	--	-----------	--	---

---

CytomX	<b>CTMX-M-2029-001: A Phase I/II, First-in-human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-Cell Lymphomas</b>	Treatment	<b>START Midwest</b> Investigators	START Midwest (616) 954-5554
--------	---	-----------	---------------------------------------	---------------------------------